Real-life data on treatment and outcomes in advanced ovarian cancer : An observational, multinational cohort study (RESPONSE trial)

Show full item record



Permalink

http://hdl.handle.net/10138/346667

Citation

Marth , C , Abreu , M H , Andersen , K K , Aro , K M , de Lurdes Batarda , M , Boll , D , Ekmann-Gade , A W , Haltia , U-M , Hansen , J , Haug , A J , Hogdall , C , Korach , J , Lassus , H , Lindemann , K , Van Nieuwenhuysen , E , Ottevanger , P B , Polterauer , S & Schnack , T H 2022 , ' Real-life data on treatment and outcomes in advanced ovarian cancer : An observational, multinational cohort study (RESPONSE trial) ' , Cancer , vol. 128 , no. 16 , pp. 3080-3089 . https://doi.org/10.1002/cncr.34350

Title: Real-life data on treatment and outcomes in advanced ovarian cancer : An observational, multinational cohort study (RESPONSE trial)
Author: Marth, Christian; Abreu, Miguel Henriques; Andersen, Klaus Kaae; Aro, Karoliina M.; de Lurdes Batarda, Maria; Boll, Dorry; Ekmann-Gade, Anne Weng; Haltia, Ulla-Maija; Hansen, Jesper; Haug, Ala Jabri; Hogdall, Claus; Korach, Jacob; Lassus, Heini; Lindemann, Kristina; Van Nieuwenhuysen, Els; Ottevanger, Petronella B.; Polterauer, Stephan; Schnack, Tine Henrichsen
Contributor organization: Clinicum
HUS Gynecology and Obstetrics
Department of Obstetrics and Gynecology
University of Helsinki
Date: 2022-08-15
Language: eng
Number of pages: 10
Belongs to series: Cancer
ISSN: 0008-543X
DOI: https://doi.org/10.1002/cncr.34350
URI: http://hdl.handle.net/10138/346667
Abstract: Background This study aimed to describe the treatment strategies and outcomes for women with newly diagnosed advanced high-grade serous or endometrioid ovarian cancer (OC). Methods This observational study collected real-world medical record data from eight Western countries on the diagnostic workup, clinical outcomes, and treatment of adult women with newly diagnosed advanced (Stage III-IV) high-grade serous or endometrioid OC. Patients were selected backward in time from April 1, 2018 (the index date), with a target of 120 patients set per country, followed for >= 20 months. Results Of the 1119 women included, 66.9% had Stage III disease, 11.7% had a deleterious BRCA mutation, and 26.6% received bevacizumab; 40.8% and 39.3% underwent primary debulking surgery (PDS) and interval debulking surgery (IDS), respectively. Of the patients who underwent PDS, 55.5% had no visible residual disease (VRD); 63.9% of the IDS patients had no VRD. According to physician-assessed responses (at the first assessment after diagnosis and treatment), 53.2% of the total population had a complete response and 25.7% had a partial response to first-line chemotherapy after surgery. After >= 20 months of follow-up, 32.9% of the patients were disease-free, 46.4% had progressive disease, and 20.6% had died. Bevacizumab use had a significant positive effect on overall survival (hazard ratio [HR], 0.62; 95% CI, 0.42-0.91; p = .01). A deleterious BRCA status had a significant positive effect on progression-free survival (HR, 0.60; 95% CI, 0.41-0.84; p < .01). Conclusions Women with advanced high-grade serous or endometrioid OC have a poor prognosis. Bevacizumab use and a deleterious BRCA status were found to improve survival in this real-world population. Lay summary Patients with advanced (Stage III or IV) ovarian cancer (OC) have a poor prognosis. The standard treatment options of surgery and chemotherapy extend life beyond diagnosis for 5 years or more in only approximately 45% of patients. This study was aimed at describing the standard of care in eight Western countries and estimating how many patients who are diagnosed with high-grade serous or endometrioid OC could potentially be eligible for first-line poly(adenosine diphosphate ribose) polymerase inhibitor (PARPi) maintenance therapy. The results highlight the poor prognosis for these patients and suggest that a significant proportion (79%) would potentially be eligible for first-line PARPi maintenance treatment.
Subject: bevacizumab
first-line treatment
ovarian cancer
poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor
real-world data
HOMOLOGOUS RECOMBINATION DEFICIENCY
OLAPARIB PLUS BEVACIZUMAB
MAINTENANCE OLAPARIB
RISK
3122 Cancers
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Cancer_2022_Mar ... ncer_An_observational_.pdf 383.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record